pSivida resubmits NDA for Iluvien; Lincoln Pharmaceuticals launches ARH1;

> pSivida, which develops sustained-release drug delivery products for treatment of back-of-the-eye diseases, has resubmited its new drug application for the investigational drug Iluvien, which treats diabetic macular edema. pSivida release

> India's Lincoln Pharmaceuticals launches its antimalarial drug ARH1, which uses "dose optimization technology" as its delivery system. Report

> Peter Cohan: Can SpringLeaf make chemo and outpatient treatment? Column

> The FDA has accepted a new drug application for Insys Therapeutics' Fentanyl SL Spray, a sublinqual delivery system for cancer patients suffering from pain. Item

> Bio-Path Holdings uses liposome-based drug delivery technology in conjunction with the company's anti-sense nucleic acid cancer therapeutic. It's currently in Phase I clinical trials for treatment of various forms of leukemia and myelodysplastic syndrome. More here

> Greystone Research Associates: Transmucosal drug delivery gaining interest in niche markets. Release

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.